Disclosed herein are methods of treating retinopathy of prematurity (ROP) in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula la or Structural Formula II described herein, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of inhibiting the destruction of retinal blood vessels in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula la or Structural Formula II, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating hyperoxia in a premature and/or low birth weight infant in need thereof, comprising administering to the infant an effective amount of a compound represented by Structural Formula I, Structural Formula la or Structural Formula II, or a pharmaceutically acceptable salt thereof. By using the methods disclosed herein, particularly when an infant is hyperoxic, oxygen toxicity to the retina of the eye can be inhibited without restricting oxygen supplementation, which is often necessary to sustain the life of premature infants.Linvention concerne des procédés pour traiter une rétinopathie des prématurés (ROP) chez un nourrisson prématuré et/ou ayant un poids insuffisant à la naissance en ayant besoin, comprenant ladministration au nourrisson dune quantité efficace dun composé représenté par la formule structurelle I, la formule structurelle Ia ou la formule structurelle II décrite dans la présente invention, ou un sel pharmaceutiquement acceptable de ce dernier. Linvention concerne également des procédés pour inhiber la destruction des vaisseaux sanguins rétiniens chez un nourrisson prématuré et/ou ayant un poids insuffisant à la naissance en ayant besoin, comprenant ladministration au nourrisson dune quantité efficace dun c
